 Joshua Gowin
Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Reward | 7 | 2023 | 211 | 2.690 |
Why?
| | Delay Discounting | 3 | 2023 | 15 | 2.110 |
Why?
| | Alcoholism | 8 | 2023 | 715 | 1.970 |
Why?
| | Substance-Related Disorders | 11 | 2022 | 946 | 1.900 |
Why?
| | Risk-Taking | 5 | 2020 | 333 | 1.690 |
Why?
| | Binge Drinking | 3 | 2020 | 32 | 1.410 |
Why?
| | Aggression | 6 | 2015 | 184 | 1.280 |
Why?
| | Gambling | 2 | 2020 | 31 | 1.250 |
Why?
| | Neuroimaging | 4 | 2019 | 248 | 1.250 |
Why?
| | Cerebral Cortex | 4 | 2019 | 381 | 1.240 |
Why?
| | Amphetamine-Related Disorders | 3 | 2015 | 28 | 1.010 |
Why?
| | Craving | 4 | 2020 | 32 | 1.010 |
Why?
| | Mental Disorders | 3 | 2023 | 891 | 0.980 |
Why?
| | Ethanol | 7 | 2020 | 548 | 0.970 |
Why?
| | Alcohol Drinking | 6 | 2020 | 655 | 0.900 |
Why?
| | Impulsive Behavior | 5 | 2019 | 110 | 0.880 |
Why?
| | Methamphetamine | 4 | 2019 | 51 | 0.810 |
Why?
| | Narcotic Antagonists | 1 | 2023 | 136 | 0.790 |
Why?
| | Ventral Striatum | 1 | 2021 | 8 | 0.770 |
Why?
| | Brain Mapping | 7 | 2024 | 522 | 0.750 |
Why?
| | Magnetic Resonance Imaging | 11 | 2024 | 3053 | 0.720 |
Why?
| | ROC Curve | 2 | 2019 | 448 | 0.680 |
Why?
| | Schizophrenia | 1 | 2023 | 415 | 0.670 |
Why?
| | Varenicline | 2 | 2016 | 22 | 0.650 |
Why?
| | Personality | 2 | 2015 | 113 | 0.550 |
Why?
| | Antisocial Personality Disorder | 3 | 2013 | 156 | 0.550 |
Why?
| | Alcohol-Related Disorders | 1 | 2017 | 113 | 0.530 |
Why?
| | Facial Expression | 1 | 2016 | 60 | 0.510 |
Why?
| | Depressive Disorder, Major | 1 | 2019 | 300 | 0.510 |
Why?
| | Personality Tests | 1 | 2015 | 15 | 0.500 |
Why?
| | Machine Learning | 1 | 2019 | 318 | 0.500 |
Why?
| | Learning | 1 | 2019 | 352 | 0.500 |
Why?
| | Neostriatum | 1 | 2015 | 29 | 0.490 |
Why?
| | Brain | 7 | 2024 | 2372 | 0.490 |
Why?
| | Amygdala | 1 | 2016 | 170 | 0.480 |
Why?
| | Emotions | 5 | 2024 | 472 | 0.450 |
Why?
| | Gyrus Cinguli | 1 | 2013 | 70 | 0.440 |
Why?
| | Fear | 1 | 2016 | 291 | 0.440 |
Why?
| | Adult Survivors of Child Abuse | 1 | 2013 | 20 | 0.420 |
Why?
| | Central Nervous System Stimulants | 1 | 2013 | 139 | 0.400 |
Why?
| | Cognition | 1 | 2019 | 983 | 0.400 |
Why?
| | Young Adult | 9 | 2022 | 10478 | 0.390 |
Why?
| | GABA Uptake Inhibitors | 1 | 2011 | 1 | 0.390 |
Why?
| | Nipecotic Acids | 1 | 2011 | 2 | 0.390 |
Why?
| | Saliva | 1 | 2013 | 189 | 0.380 |
Why?
| | Humans | 33 | 2024 | 114937 | 0.380 |
Why?
| | Psychopathology | 2 | 2023 | 47 | 0.380 |
Why?
| | Hydrocortisone | 1 | 2013 | 270 | 0.370 |
Why?
| | Tryptamines | 1 | 2010 | 3 | 0.360 |
Why?
| | Decision Making | 2 | 2013 | 781 | 0.350 |
Why?
| | Serotonin Receptor Agonists | 1 | 2010 | 27 | 0.350 |
Why?
| | Oxazolidinones | 1 | 2010 | 14 | 0.350 |
Why?
| | Adult | 18 | 2020 | 30608 | 0.350 |
Why?
| | Alprazolam | 1 | 2009 | 6 | 0.340 |
Why?
| | Game Theory | 1 | 2009 | 9 | 0.340 |
Why?
| | GABA Modulators | 1 | 2009 | 7 | 0.340 |
Why?
| | Recurrence | 3 | 2019 | 937 | 0.320 |
Why?
| | Cues | 2 | 2021 | 301 | 0.300 |
Why?
| | Endocannabinoids | 2 | 2018 | 37 | 0.290 |
Why?
| | Functional Neuroimaging | 2 | 2019 | 68 | 0.290 |
Why?
| | Pain | 1 | 2013 | 710 | 0.290 |
Why?
| | Cooperative Behavior | 1 | 2009 | 383 | 0.280 |
Why?
| | Interpersonal Relations | 1 | 2009 | 339 | 0.270 |
Why?
| | Male | 18 | 2020 | 55663 | 0.260 |
Why?
| | Double-Blind Method | 4 | 2016 | 1663 | 0.260 |
Why?
| | Female | 18 | 2020 | 59581 | 0.250 |
Why?
| | Self Administration | 4 | 2019 | 123 | 0.250 |
Why?
| | Likelihood Functions | 2 | 2015 | 126 | 0.230 |
Why?
| | Receptors, Opioid | 1 | 2023 | 19 | 0.220 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2011 | 1856 | 0.210 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1080 | 0.210 |
Why?
| | Administration, Intravenous | 3 | 2018 | 125 | 0.210 |
Why?
| | Naltrexone | 1 | 2023 | 83 | 0.210 |
Why?
| | Neuropsychological Tests | 3 | 2015 | 913 | 0.200 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 4407 | 0.190 |
Why?
| | Positron-Emission Tomography | 2 | 2019 | 265 | 0.180 |
Why?
| | Violence | 2 | 2013 | 200 | 0.170 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2019 | 159 | 0.170 |
Why?
| | Substance Abuse Treatment Centers | 1 | 2020 | 42 | 0.170 |
Why?
| | Central Nervous System Depressants | 2 | 2017 | 82 | 0.170 |
Why?
| | Placebos | 2 | 2010 | 198 | 0.170 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2019 | 43 | 0.160 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2018 | 35 | 0.160 |
Why?
| | Pilot Projects | 1 | 2023 | 1372 | 0.160 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2018 | 28 | 0.160 |
Why?
| | Punishment | 1 | 2018 | 20 | 0.160 |
Why?
| | Risk | 2 | 2019 | 815 | 0.150 |
Why?
| | Nicotinic Agonists | 2 | 2016 | 100 | 0.150 |
Why?
| | Social Justice | 1 | 2018 | 67 | 0.150 |
Why?
| | Receptors, Opioid, mu | 1 | 2018 | 52 | 0.150 |
Why?
| | Blood Alcohol Content | 1 | 2017 | 5 | 0.150 |
Why?
| | Motivation | 1 | 2021 | 495 | 0.140 |
Why?
| | Medical History Taking | 1 | 2017 | 114 | 0.140 |
Why?
| | Amidohydrolases | 1 | 2017 | 28 | 0.140 |
Why?
| | Tobacco Use Disorder | 1 | 2019 | 234 | 0.140 |
Why?
| | Nerve Net | 1 | 2019 | 225 | 0.140 |
Why?
| | Inpatients | 1 | 2020 | 380 | 0.130 |
Why?
| | Analgesics, Opioid | 1 | 2023 | 773 | 0.130 |
Why?
| | Affect | 1 | 2018 | 246 | 0.130 |
Why?
| | Sex Factors | 2 | 2019 | 1721 | 0.130 |
Why?
| | Alcohol Deterrents | 1 | 2015 | 17 | 0.130 |
Why?
| | Suicidal Ideation | 1 | 2020 | 397 | 0.130 |
Why?
| | Rest | 1 | 2015 | 103 | 0.120 |
Why?
| | Infusions, Intravenous | 1 | 2016 | 372 | 0.120 |
Why?
| | Self Report | 2 | 2016 | 696 | 0.120 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 347 | 0.120 |
Why?
| | Functional Laterality | 1 | 2015 | 197 | 0.120 |
Why?
| | Risk Factors | 3 | 2020 | 8637 | 0.120 |
Why?
| | Neural Pathways | 1 | 2015 | 258 | 0.110 |
Why?
| | Comorbidity | 1 | 2018 | 1458 | 0.110 |
Why?
| | Compulsive Behavior | 1 | 2013 | 5 | 0.110 |
Why?
| | Logistic Models | 1 | 2019 | 1844 | 0.110 |
Why?
| | Analysis of Variance | 2 | 2013 | 1227 | 0.110 |
Why?
| | Models, Neurological | 1 | 2015 | 212 | 0.110 |
Why?
| | Exploratory Behavior | 1 | 2013 | 83 | 0.110 |
Why?
| | Psychological Tests | 1 | 2013 | 120 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2102 | 0.110 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2013 | 483 | 0.100 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2382 | 0.100 |
Why?
| | Pituitary-Adrenal System | 1 | 2013 | 131 | 0.100 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2013 | 165 | 0.100 |
Why?
| | Middle Aged | 4 | 2020 | 26806 | 0.090 |
Why?
| | Patient Dropouts | 1 | 2011 | 66 | 0.090 |
Why?
| | Texas | 1 | 2011 | 188 | 0.090 |
Why?
| | Survival Analysis | 1 | 2013 | 1220 | 0.090 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2011 | 231 | 0.090 |
Why?
| | Regression Analysis | 1 | 2013 | 947 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1801 | 0.090 |
Why?
| | Breath Tests | 1 | 2010 | 82 | 0.090 |
Why?
| | Bayes Theorem | 1 | 2011 | 331 | 0.080 |
Why?
| | Drug Synergism | 1 | 2010 | 316 | 0.080 |
Why?
| | Anticonvulsants | 1 | 2011 | 178 | 0.080 |
Why?
| | Psychometrics | 1 | 2013 | 608 | 0.080 |
Why?
| | Fructose | 1 | 2009 | 100 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 4635 | 0.070 |
Why?
| | Social Behavior | 1 | 2009 | 267 | 0.070 |
Why?
| | Prognosis | 1 | 2013 | 3344 | 0.070 |
Why?
| | Adolescent | 1 | 2023 | 17829 | 0.060 |
Why?
| | Signal Transduction | 1 | 2018 | 4525 | 0.060 |
Why?
| | Follow-Up Studies | 1 | 2013 | 4427 | 0.060 |
Why?
| | Child | 1 | 2023 | 18366 | 0.060 |
Why?
| | Genotype | 2 | 2018 | 1775 | 0.050 |
Why?
| | Animals | 4 | 2019 | 31839 | 0.050 |
Why?
| | Prospective Studies | 1 | 2013 | 6218 | 0.050 |
Why?
| | Time Factors | 1 | 2011 | 6125 | 0.050 |
Why?
| | Suicide, Attempted | 1 | 2020 | 313 | 0.040 |
Why?
| | Gene Frequency | 1 | 2017 | 481 | 0.030 |
Why?
| | Anticipation, Psychological | 1 | 2015 | 18 | 0.030 |
Why?
| | Alleles | 1 | 2018 | 791 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2017 | 295 | 0.030 |
Why?
| | Suicide | 1 | 2020 | 502 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 2015 | 220 | 0.030 |
Why?
| | Personality Inventory | 1 | 2013 | 132 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2018 | 1197 | 0.020 |
Why?
| | Oxygen | 1 | 2015 | 853 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 1893 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2542 | 0.020 |
Why?
| | Aged | 1 | 2020 | 19122 | 0.010 |
Why?
|
|
Gowin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|